Ocata Therapeutics Inc fka OCAT

[Paulness]

This is a well written and thought out post

2011 should produce some very substantive results with regard to ACTC and other regenerative companies. The amount of shares outstanding (currently over 1.1 billion) is not a barrier to higher prices for this stock as the conservative estimate pegs a 25 billion market in the US (not including the rest of the world). That would equate to around 20.00 to 25.00 per share if they find a way to bring this to market. If the results are positive, I could see some big players like MRK or PFE coming into the mix. I do not see reversing as they are not in danger of being delisted from the OTC...the stock will grow organically based on the results from the trials currently underway. The beauty of this particular stock can be found in the patents. The company knows more than anyone (including the FDA) about how this process works and the rest of the companies doing research will ultimately have do business with ACTC to purchase the technology that allows it to be safely used from the embryo.

I agree that this company is way undervalued at this point. By the time investors wake up to this new technology, the price will be well on its way to much higher levels. At .175 per share...its a steal...and it really is just a matter of time before the results are released in 2011.